Cargando…

Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016

Background and study aims  Pancreatic cancer (PC) is the fourth most common cause of cancer death in the United States. Previous studies have suggested a survival benefit for endoscopic ultrasound (EUS), an important tool for diagnosis and staging of PC. This study aims to describe EUS use over time...

Descripción completa

Detalles Bibliográficos
Autores principales: Rustgi, Sheila D., Zylberberg, Haley M., Amin, Sunil, Aronson, Anne, Nagula, Satish, DiMaio, Christopher J., Kumta, Nikhil A., Lucas, Aimee L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759943/
https://www.ncbi.nlm.nih.gov/pubmed/35047331
http://dx.doi.org/10.1055/a-1608-0856
_version_ 1784633214960140288
author Rustgi, Sheila D.
Zylberberg, Haley M.
Amin, Sunil
Aronson, Anne
Nagula, Satish
DiMaio, Christopher J.
Kumta, Nikhil A.
Lucas, Aimee L.
author_facet Rustgi, Sheila D.
Zylberberg, Haley M.
Amin, Sunil
Aronson, Anne
Nagula, Satish
DiMaio, Christopher J.
Kumta, Nikhil A.
Lucas, Aimee L.
author_sort Rustgi, Sheila D.
collection PubMed
description Background and study aims  Pancreatic cancer (PC) is the fourth most common cause of cancer death in the United States. Previous studies have suggested a survival benefit for endoscopic ultrasound (EUS), an important tool for diagnosis and staging of PC. This study aims to describe EUS use over time and identify factors associated with EUS use and its impact on survival. Patients and methods  This was a retrospective review of the Surveillance, Epidemiology and End Results (SEER) database linked with Medicare claims. EUS use, clinical and demographic characteristics were evaluated. Chi-squared analysis, Cochran-Armitage test for trend, and logistic regression were used to identify associations between sociodemographic and clinical factors and EUS. Kaplan-Meier and Cox proportional hazard ratios were used for survival analysis. Results  EUS use rose during the time period, from 7.4 % of patients in 2000 to 32.4 % in 2015. Patient diversity increased, with a rising share of older, non-White patients with higher Charlson comorbidity scores. Both clinical (receipt of other therapies, PC stage) and nonclinical factors (region of country, year of diagnosis) were associated with receipt of EUS. While EUS was associated with a survival improvement early in the study period, this effect did not persist for PC patients diagnosed in 2012 to 2015 (median survival 3 month ± standard deviation [SD] 9.8 months without vs. 4 months ± SD 8 months with EUS). Conclusions  Our data support previous studies, which suggest a survival benefit for EUS when it was infrequently used, but finds that benefit was attenuated as EUS became more widely available.
format Online
Article
Text
id pubmed-8759943
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-87599432022-01-18 Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016 Rustgi, Sheila D. Zylberberg, Haley M. Amin, Sunil Aronson, Anne Nagula, Satish DiMaio, Christopher J. Kumta, Nikhil A. Lucas, Aimee L. Endosc Int Open Background and study aims  Pancreatic cancer (PC) is the fourth most common cause of cancer death in the United States. Previous studies have suggested a survival benefit for endoscopic ultrasound (EUS), an important tool for diagnosis and staging of PC. This study aims to describe EUS use over time and identify factors associated with EUS use and its impact on survival. Patients and methods  This was a retrospective review of the Surveillance, Epidemiology and End Results (SEER) database linked with Medicare claims. EUS use, clinical and demographic characteristics were evaluated. Chi-squared analysis, Cochran-Armitage test for trend, and logistic regression were used to identify associations between sociodemographic and clinical factors and EUS. Kaplan-Meier and Cox proportional hazard ratios were used for survival analysis. Results  EUS use rose during the time period, from 7.4 % of patients in 2000 to 32.4 % in 2015. Patient diversity increased, with a rising share of older, non-White patients with higher Charlson comorbidity scores. Both clinical (receipt of other therapies, PC stage) and nonclinical factors (region of country, year of diagnosis) were associated with receipt of EUS. While EUS was associated with a survival improvement early in the study period, this effect did not persist for PC patients diagnosed in 2012 to 2015 (median survival 3 month ± standard deviation [SD] 9.8 months without vs. 4 months ± SD 8 months with EUS). Conclusions  Our data support previous studies, which suggest a survival benefit for EUS when it was infrequently used, but finds that benefit was attenuated as EUS became more widely available. Georg Thieme Verlag KG 2022-01-14 /pmc/articles/PMC8759943/ /pubmed/35047331 http://dx.doi.org/10.1055/a-1608-0856 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Rustgi, Sheila D.
Zylberberg, Haley M.
Amin, Sunil
Aronson, Anne
Nagula, Satish
DiMaio, Christopher J.
Kumta, Nikhil A.
Lucas, Aimee L.
Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016
title Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016
title_full Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016
title_fullStr Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016
title_full_unstemmed Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016
title_short Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016
title_sort use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759943/
https://www.ncbi.nlm.nih.gov/pubmed/35047331
http://dx.doi.org/10.1055/a-1608-0856
work_keys_str_mv AT rustgisheilad useofendoscopicultrasoundforpancreaticcancerfrom2000to2016
AT zylberberghaleym useofendoscopicultrasoundforpancreaticcancerfrom2000to2016
AT aminsunil useofendoscopicultrasoundforpancreaticcancerfrom2000to2016
AT aronsonanne useofendoscopicultrasoundforpancreaticcancerfrom2000to2016
AT nagulasatish useofendoscopicultrasoundforpancreaticcancerfrom2000to2016
AT dimaiochristopherj useofendoscopicultrasoundforpancreaticcancerfrom2000to2016
AT kumtanikhila useofendoscopicultrasoundforpancreaticcancerfrom2000to2016
AT lucasaimeel useofendoscopicultrasoundforpancreaticcancerfrom2000to2016